Ryan Brewer is an experienced corporate lawyer whose practice focuses on corporate and securities law matters. He advises on a wide range of domestic and cross-border capital markets transactions and has experience representing a diverse range of clients from industries and sectors, including life sciences, healthcare, technology, defense, FinTech and financial services, energy, telecom, consumer and retail, industrial, REITs and SPACs. Mr. Brewer also advises public companies on disclosure and other federal securities law and corporate governance matters.

Mr. Brewer regularly represents both issuers and underwriters in initial public offerings, follow-on and secondary equity offerings, investment grade and other debt offerings and offerings of preferred and hybrid securities.

Prior to joining WilmerHale, Mr. Brewer was a corporate and securities associate at another law firm in Washington DC where he focused on public offerings, private placements, corporate governance, fund formation and mergers and acquisitions. Previously, he served as a law clerk at the Overseas Private Investment Corporation, the Commercial Law Development Program at the US Department of Commerce, and a law firm in Milan, Italy.


  • Represented Thermo Fisher Scientific Inc. in connection with its public offering of $1.2B USD and €1.25B EUR Notes in November 2022, and in connection with pricing an offering of ¥109.5 billion aggregate principal amount of yen-denominated senior notes in October 2022.
  • Represented one of the nation’s largest and most diversified television broadcasting companies in connection with a private Rule 144A offering of $3.05 billion of senior secured notes and $1.825 billion of senior unsecured notes—the largest US high-yield bond offering since 2016.
  • Represented a NYSE-listed mixed-use property real estate investment trusts in connection with a underwritten public offering of $400 million of green bonds.
  • Represented a Nasdaq-listed independent oil and natural gas company in its sale to an NYSE-listed independent oil and natural gas company for $71 million.
  • Represented a NYSE-listed triple net lease real estate investment trusts in more than $2 billion of underwritten public offerings of common stock, preferred stock, senior unsecured notes and convertible notes.
  • Represented a Nasdaq-listed leading, clinical stage gene editing company in connection with a $265 million underwritten public offering of common stock.
  • Represented a Nasdaq-listed full-service investment banking and asset management firm in its sale to a Nasdaq-listed full-service investment bank and wealth management firm for $24 million.
  • Represented the largest independent publicly traded business intelligence company, in connection with a Rule 144A offering of $1.05 billion of convertible senior notes—the first convertible note offering in which the stated use of proceeds was to purchase bitcoin.
  • Represented numerous SEC reporting companies in connection with Securities Exchange Act compliance.
  • Advised the underwriters and exchange agents in multiple transactions by Avadel Pharmaceutics plc (Nasdaq: AVDL), including a $143.8 million follow-on equity offering and a $96 million exchange of convertible notes to support the potential commercialization of Avadel’s LUMRYZ™ for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.

Insights & News


  • Education

    • JD, Georgetown University Law Center, 2017

      cum laude International Trade Editor, Georgetown Journal of International Law
    • BA, Philosophy, San Jose State University, 2014

      summa cum laude
  • Admissions

    • District of Columbia

    • New York